An official website of the United States government
Enable better access to electronic health records data and provide support for their integration with clinical and molecular data to build person-specific predictive models of disease and wellness to enable disease sub-classification and inform data-driven drug repurposing. These efforts should include better electronic phenotyping of AD through the application of machine learning methods.
2028 PAR-18-596: Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01) NOT-AG-18-001 (#9): Neuropsychiatric Symptoms in Alzheimer's Disease (NPS-AD) 1.H In Progress Enable access to electronic health records data and provide support for their integration with clinical and molecular data... DN 2018 AD Summit: 2G, 2H and 4K 2021 AD Summit: 6.C News: Electronic health records-based tool uses data to detect undiagnosed dementia Workshop: Deriving Common Data Elements from Real-Word Data for Alzheimer’s Disease and Alzheimer’s Disease Related Dementias Workshop: The Future of Population-Based Studies in Alzheimer’s Disease and Related Dementia Research: Setting Future Scientific Priorities Population Studies and Precision Medicine Construct Large-Scale Phenomes of Diseases and Drugs and Develop Data-Driven Systems Approaches to Understand Genetic Links Between Alzheimer’s Disease and Neuropsychiatric Symptoms 2019
- Hold an advisory meeting focused on understanding and overcoming barriers to sharing and usability of electronic health records in the US and globally.
- Initiate at least one research program focused on electronic phenotyping of AD through the application of machine learning methods and integration of EHR data with genomic, molecular, clinical and other patient relevant data to build person-specific models of disease, to identify disease sub-types and to identify biomarkers and molecular signatures for these subtypes and to advance data-driven drug repurposing.
Summary of Key Accomplishments
In 2021, NIA supported an expert panel meeting that identified opportunities for: expanding data access — including electronic health records — and integration to support interventional AD/ADRD studies; using big data to address health disparities across AD/ADRD populations; public-private data sharing collaborations and data licensing; and strategies for using big data for clinical interventions.
The use of EHRs is an integral part of many NIA-supported population studies, including the Psych-AD program and the Drug Repurposing and Combination Therapy program. These projects seek to develop interactive web applications and tools for the broad scientific community that can be used to explore the links between neuropsychiatric symptoms and AD.
The key accomplishments summary is current as of July 2022.